Expand EWTX Menu
EWTX MENU

EWTX Latest Press Releases

-- September 2, 2026 --

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PRNewswire 8:01 AM

-- August 24, 2026 --

Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026 PRNewswire 8:01 AM

-- August 6, 2026 --

Edgewise Therapeutics Reports Second Quarter 2026 Financial Results PRNewswire 8:00 AM

-- July 13, 2026 --

Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline PRNewswire 8:30 AM
Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business PRNewswire 8:30 AM

-- July 1, 2026 --

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PRNewswire 8:00 AM

-- June 16, 2026 --

Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum Globe Newswire 10:18 AM
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM) PRNewswire 7:00 AM

-- June 3, 2026 --

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PRNewswire 4:01 PM

-- June 1, 2026 --

Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline PRNewswire 8:30 AM
Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business PRNewswire 8:30 AM

-- May 12, 2026 --

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026 PRNewswire 8:00 AM
Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma Globe Newswire 7:05 AM

-- May 7, 2026 --

Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications PRNewswire 8:00 AM

-- May 4, 2026 --

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PRNewswire 8:00 AM
Market Data Delayed 15 Minutes